NCT05367440: PETRANHA

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

Active, enrolled Phase 1, PHASE2 Last updated 8 December 2025

What this trial tests

Phase 1, PHASE2 trial testing AZD5305 in Metastatic Prostate Cancer in 174 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 June 2022

Primary endpoint
11 April 2031

11 April 2031

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	174
Start date	2 June 2022
Primary completion	11 April 2031
Estimated completion	11 April 2031
Sites	20 locations across Italy, United Kingdom, United States, Australia

Drugs / interventions tested

• AZD5305 — full drug profile →
• Enzalutamide (enzalutamide) — full drug profile →
• Abiraterone Acetate (ABIRATERONE) — full drug profile →
• Darolutamide
• Apalutamide (apalutamide) — full drug profile →

Conditions studied

• Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, male only, with Metastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. A new wave of innovations within the DNA damage response.
   Li Q, Qian W, Zhang Y, Hu L, et al · · 2023 · cited 85× · PMID 37679326 · DOI 10.1038/s41392-023-01548-8
2. Mechanism of PARP inhibitor resistance and potential overcoming strategies.
   Fu X, Li P, Zhou Q, He R, et al · · 2024 · cited 45× · PMID 37588193 · DOI 10.1016/j.gendis.2023.02.014
3. DNA repair and the contribution to chemotherapy resistance.
   Nesic K, Parker P, Swisher EM, Krais JJ. · · 2025 · cited 16× · PMID 40420317 · DOI 10.1186/s13073-025-01488-8
4. Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
   Zheng J, Li Z, Min W. · · 2022 · cited 16× · PMID 36756144 · DOI 10.3389/fphar.2022.979873
5. Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.
   Kostos L, Tran B, Azad AA. · · 2024 · cited 11× · PMID 39060912 · DOI 10.1007/s40265-024-02071-y
6. Perspectives on cancer therapy-synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges.
   Peng S, Long M, Chen Q, Yin Z, et al · · 2025 · cited 8× · PMID 40240755 · DOI 10.1038/s41420-025-02418-8
7. Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs.
   Gong X, Liu C, Tang H, Wu S, et al · · 2024 · cited 4× · PMID 39655075 · DOI 10.3389/fonc.2024.1460412
8. Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer.
   Calabrese M, Saporita I, Turco F, Gillessen S, et al · · 2023 · cited 4× · PMID 38203248 · DOI 10.3390/ijms25010078